Free Trial
NYSE:QGEN

Qiagen (QGEN) Stock Price, News & Analysis

Qiagen logo
$41.27 -0.82 (-1.95%)
(As of 11/15/2024 ET)

About Qiagen Stock (NYSE:QGEN)

Key Stats

Today's Range
$40.97
$41.97
50-Day Range
$41.28
$46.57
52-Week Range
$39.03
$47.44
Volume
1.23 million shs
Average Volume
849,314 shs
Market Capitalization
$9.42 billion
P/E Ratio
105.82
Dividend Yield
N/A
Price Target
$50.88
Consensus Rating
Moderate Buy

Company Overview

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for prenatal testing and detection of sexually transmitted diseases and HPV, as well as assays for analysis of genomic variants, such as mutations, insertions, deletions, and fusions; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. In addition, it offers PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. Further, the company provides predefined and custom NGS gene panels, library prep kits and components, and whole genome amplification; QIAGEN consumables and instruments, as well as bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.

Qiagen Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
86th Percentile Overall Score

QGEN MarketRank™: 

Qiagen scored higher than 86% of companies evaluated by MarketBeat, and ranked 175th out of 970 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Qiagen has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 6 buy ratings, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Qiagen has only been the subject of 2 research reports in the past 90 days.

  • Read more about Qiagen's stock forecast and price target.
  • Earnings Growth

    Earnings for Qiagen are expected to grow by 4.13% in the coming year, from $2.18 to $2.27 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Qiagen is 105.82, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 109.33.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Qiagen is 105.82, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 62.60.

  • Price to Earnings Growth Ratio

    Qiagen has a PEG Ratio of 3.14. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Qiagen has a P/B Ratio of 2.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Qiagen's valuation and earnings.
  • Percentage of Shares Shorted

    1.61% of the float of Qiagen has been sold short.
  • Short Interest Ratio / Days to Cover

    Qiagen has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Qiagen has recently decreased by 8.70%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Qiagen does not currently pay a dividend.

  • Dividend Growth

    Qiagen does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.61% of the float of Qiagen has been sold short.
  • Short Interest Ratio / Days to Cover

    Qiagen has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Qiagen has recently decreased by 8.70%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Qiagen has a news sentiment score of 0.77. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 12 news articles for Qiagen this week, compared to 5 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Qiagen insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 9.00% of the stock of Qiagen is held by insiders.

  • Percentage Held by Institutions

    70.00% of the stock of Qiagen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Qiagen's insider trading history.
Receive QGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Qiagen and its competitors with MarketBeat's FREE daily newsletter.

QGEN Stock News Headlines

Qiagen enters three-year partnership with McGill University
What is William Blair's Estimate for Qiagen FY2024 Earnings?
The only candlestick pattern worth a darn
It’s widely known that 80% of daily market action is driven by Wall Street algorithms… Now, most people think of the algorithms are “bad” When in reality, they are neither good nor bad… They are simply programmed to buy and sell certain stocks over and over again… But here is the thing… They are predictable… They typically buy the same stocks at the same levels over and over again…
UBS Remains a Hold on Qiagen (QGEN)
Qiagen’s Financial Growth and Rising Debt in Q3 2024
Qiagen’s Solid Performance with Potential Upside Amid Mixed Signals
Qiagen (QGEN) Receives a Hold from Stifel Nicolaus
See More Headlines

QGEN Stock Analysis - Frequently Asked Questions

Qiagen's stock was trading at $44.7732 on January 1st, 2024. Since then, QGEN stock has decreased by 7.8% and is now trading at $41.27.
View the best growth stocks for 2024 here
.

Qiagen (NYSE:QGEN) announced its quarterly earnings data on Wednesday, July, 31st. The company reported $0.55 earnings per share for the quarter, topping the consensus estimate of $0.52 by $0.03. The firm's revenue for the quarter was down .2% compared to the same quarter last year.

Qiagen shares reverse split on Tuesday, January 30th 2024. The 24.25-25 reverse split was announced on Tuesday, January 30th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 97 shares after the split.

Top institutional shareholders of Qiagen include Massachusetts Financial Services Co. MA (10.13%), Wellington Management Group LLP (9.31%), Nuance Investments LLC (1.97%) and Victory Capital Management Inc. (1.13%).

Shares of QGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Qiagen investors own include NVIDIA (NVDA), Tesla (TSLA), Meta Platforms (META), Netflix (NFLX), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM) and PayPal (PYPL).

Company Calendar

Last Earnings
7/31/2024
Today
11/17/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
2/04/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Employees
5,967
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$50.88
High Stock Price Target
$60.00
Low Stock Price Target
$45.00
Potential Upside/Downside
+23.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
10 Analysts

Profitability

Net Income
$341.30 million
Pretax Margin
5.81%

Debt

Sales & Book Value

Annual Sales
$1.97 billion
Cash Flow
$3.12 per share
Book Value
$15.47 per share

Miscellaneous

Free Float
207,665,000
Market Cap
$9.42 billion
Optionable
Optionable
Beta
0.41
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NYSE:QGEN) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners